Strides Pharma Acquires Sandoz Brands to Expand Africa Presence
Filing Summary
Strides Pharma Science Ltd. has announced the acquisition of multiple branded generic products from Sandoz AG for its Sub-Saharan Africa operations. The transaction, valued at USD 12 million, involves Strides’ step-down subsidiary, Strides Pharma International AG, acquiring and in-licensing products across anti-infective, cardiovascular, and dermatology segments. This acquisition is expected to position Strides among the top five pharmaceutical companies in the region by sales. The transaction is anticipated to close by the end of Q2 FY27, subject to regulatory approvals.
Strides Pharma Science Ltd. has announced the acquisition of a portfolio of branded generic products from Sandoz AG and its group entities. The acquisition is conducted through Strides’ step-down subsidiary, Strides Pharma International AG (SPIAG), and covers key markets in Sub-Saharan Africa, including Western Sahara, Ghana, Nigeria, and Kenya. This strategic move is intended to enhance Strides’ market position in the region.
The financial terms of the transaction include an initial consideration of USD 12 million, payable at closing. The acquisition is expected to be funded through internal accruals. The transaction is anticipated to be EPS-accretive, supported by profitable branded sales and improved operating leverage. The deal is structured to include both fully acquired products and select products that Strides will market on behalf of Sandoz.
The scope of the acquisition involves a portfolio of branded generics across anti-infective, cardiovascular, and dermatology therapeutic segments. Several products in this portfolio have annual sales exceeding USD 1 million, indicating established brand equity and market demand. Strides will also enter into a Manufacturing and Supply Agreement with Sandoz to ensure the continued production and supply of these products.
The acquisition aligns with Strides’ strategy to expand its presence in the Sub-Saharan Africa region. The combined business is expected to position Strides as one of the top five pharmaceutical companies in the region by sales. The transaction is designed to enhance Strides’ market reach and provide access to new therapeutic areas, leveraging the combined portfolios across a broader network of healthcare providers.
The transaction is expected to close by the end of Q2 FY27, which ends on September 30, 2026. The completion of the deal is subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.
Strides Pharma Science Ltd. is a global pharmaceutical company headquartered in Bengaluru, India. The company focuses on regulated markets and has an “in Africa for Africa” strategy, along with an institutional business to service donor-funded markets. Strides operates manufacturing sites in India, Italy, Kenya, and the United States, and specializes in “difficult to manufacture” products sold in over 100 countries.